ERBB2 and hematologic disorder: Though promising in hematological disease treatment, the efficiency of CAR‐T in solid tumors is below expectation.[45] Due to the heterogeneity of tumor markers, attempts have been made to explore the ideal target antigens on solid tumors such as anti‐human epidermal growth factor receptor 2 (HER2), which is overexpressed in breast cancer.